Suchergebnisse - "Schoergenhofer, Christian"

PubPharm (7)

1

Drug-Drug Interactions in Patients with Acute Respiratory Distress Syndrome

enthalten in: Pharmaceutics | 2024

von Bischof, T. | Schaller, C. | Buchtele, N. | +6

2

Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial

enthalten in: iScience | 2023

von Rathkolb, V. | Traugott, M. | Heinzel, A. | +25

3

Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid

enthalten in: Frontiers in medicine | 2022

von Reindl-Schwaighofer, R. | Eskandary, F. | Bartko, J. | +4

4

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

enthalten in: Frontiers in pharmacology | 2021

von Karolyi, M. | Omid, S. | Pawelka, E. | +8

5

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

enthalten in: Annals of internal medicine | 2020

von Schoergenhofer, C. | Jilma, B. | Stimpfl, T. | +2

CommentIn: Microb Drug Resist. 2022 May;28(5):611-612. - PMID 35099290

6

Endpoints for randomized controlled clinical trials for COVID-19 treatments

enthalten in: Clinical trials (London, England) | 2020

von Dodd, L. | Follmann, D. | Wang, J. | +12

CommentIn: Clin Trials. 2021 Apr;18(2):263-264. - PMID 33322940

7

Endpoints for randomized controlled clinical trials for COVID-19 treatments

enthalten in: arXiv.org | 2020

von Dodd, L. | Follmann, D. | Wang, J. | +12

1
[1]